Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Registration Number
- NCT00042029
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
- Detailed Description
The duration of treatment is 8 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 324
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HAMD-17 total score; Tolerability
- Secondary Outcome Measures
Name Time Method CGI-I Scale score; Sheehan Disability Scale